Ipsen: Bylyvay fails to show a benefit in biliary atresia, which is likely to lead to consensus cuts to 2030 sales - minor negative

研报英文原文证据摘录

Ipsen: Bylyvay fails to show a benefit in biliary atresia, which is likely to lead to consensus cuts to 2030 sales - minor negative

rities LLC, and may not be subject to FINRA Rule 2241 or 2242 restrictions on communications with covered companies, public

appearances, and trading securities held by a research analyst account.

Other Disclosures

J.P. Morgan is a marketing name for investment banking businesses of JPMorgan Chase & Co. and its subsidiaries and affiliates worldwide.

UK MIFID FICC research unbundling exemption: UK clients should refer to UK MIFID Research Unbundling exemption for details of J.P.

Morgan’s implementation of the FICC research exemption and guidance on relevant FICC research categorisation.

All research material made available to clients are simultaneously available on our client website, J.P. Morgan Markets, unless specifically

permitted by relevant laws. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research

material available on a particular stock, please contact your sales representative.

Any long form nomenclature for references to China; Hong Kong; Taiwan; and Macau within this research material are Mainland China; Hong

Kong SAR (China); Taiwan (China); and Macau SAR (China).

J.P. Morgan Research may, from time to time, write on issuers or securities targeted by economic or financial sanctions imposed or administered

by the governmental authorities of the U.S., EU, UK or other relevant jurisdictions (Sanctioned Securities). Nothing in this report is intended to

be read or construed as encouraging, facilitating, promoting or otherwise approving investment or dealing in such Sanctioned Securities. Clients